Our research focuses on understanding the fundamental and functional aspects of pharmacokinetics-pharmacodynamics (PKPD) in health and disease.
Within the area of translational PKPD we address conversion of pharmacokinetic data from the preclinical to the clinical setting. This is strongly needed for optimizing drug discovery processes and promoting efficient treatment of CNS diseases.
We are interested in brain drug delivery in relation to transport processes of both small and large molecules across the blood-brain barrier (BBB). Using the concepts and methodologies developed in the group, we are exploring brain regional drug disposition, including the influence of diseases, with focus on the pharmacologically relevant unbound concentrations. We are also studying the quantitative role of nanocarriers for improved uptake into the brain.
Our work also emphasizes the importance of bridging the expertise within academia and pharmaceutical industry in order to seek excellence in method development for better therapeutics treating CNS disorders.